Par Drugs And Chemicals Limited · PAR
Every Par Drugs And Chemicals Limited result whose ten-session window has closed, judged against the last read made before it. Open a result for the full account: the read, the sessions after, the reported figures, and every morning's read that led up to it. The company's own page →
19results judged
0read right
0read wrong
0flat / no call
19unread
21%beat the market
-4.2%avg vs market, 10d
7.5%avg move, T+1
How the reads on it fared
| Read | Judged | Right | Wrong | Flat | Hit rate | Avg vs mkt | |
|---|---|---|---|---|---|---|---|
| unread | 19 | 0 | 0 | 0 | — | -4.2% |
A company that is often read strong and often proves it is one the model understands; one that is read strong and keeps lagging is where the model is wrong about a name, and this table is where that shows first.
Reading the rows
- T+1
- the share's move on the first session after the result, from the close before it
- T+10
- the move over ten sessions, same base
- vs market
- T+10 less NIFTY 50's move over the same ten sessions — the number every read is judged on
- Run-up
- the share's move in the thirty sessions before the result
- Result
- reported profit growth against the company's own last four quarters: good, in line, bad
Each result
19 judged · newest first · open one| Result | Read | Outcome | T+1 | T+10 | vs market | Run-up | Result | Why | |
|---|---|---|---|---|---|---|---|---|---|
| 8 Aug Q1FY27 | — | unread | +2.0% | +3.1% | +4.5% | — | no figures |
|
› |
| 14 May Q4FY26 | — | unread | -9.3% | -3.8% | -3.2% | +18% | no figures |
|
› |
| 10 Feb Q3FY26 | — | unread | +3.3% | -1.4% | +0.3% | -4% | no figures |
|
› |
| 13 Nov Q2FY26 | — | unread | -4.7% | -9.3% | -10.6% | -6% | no figures |
|
› |
| 7 Aug Q1FY26 | — | unread | +4.0% | -4.5% | -6.0% | +4% | no figures |
|
› |
| 8 May Q4FY25 | — | unread | -2.9% | -0.1% | -2.5% | +5% | no figures |
|
› |
| 15 Feb Q3FY25 | — | unread | -9.8% | -39.9% | -36.2% | -26% | no figures |
|
› |
| 22 Oct Q2FY25 | — | unread | +28.8% | +34.6% | +34.6% | -6% | no figures |
|
› |
| 3 Aug Q1FY25 | — | unread | -3.5% | +1.7% | +1.8% | +5% | no figures |
|
› |
| 10 May Q4FY24 | — | unread | -2.0% | -8.4% | -12.9% | +20% | no figures |
|
› |
| 17 Feb Q3FY24 | — | unread | -5.5% | -7.0% | -8.7% | +3% | no figures |
|
› |
| 28 Oct Q2FY24 | — | unread | +5.4% | +10.5% | +8.5% | +9% | no figures |
|
› |
| 4 Aug Q1FY24 | — | unread | -4.1% | +0.4% | +0.4% | -14% | no figures |
|
› |
| 28 Apr Q4FY23 | — | unread | -6.2% | -2.4% | -5.1% | +18% | no figures |
|
› |
| 11 Feb Q3FY23 | — | unread | -4.9% | -10.2% | -7.6% | +8% | no figures |
|
› |
| 10 Nov Q2FY23 | — | unread | +13.9% | +7.8% | +6.0% | -6% | no figures |
|
› |
| 7 May Q4FY22 | — | unread | -11.6% | -13.2% | -12.0% | +6% | no figures |
|
› |
| 8 Feb Q3FY22 | — | unread | -10.5% | -15.3% | -14.6% | -10% | no figures |
|
› |
| 10 Nov Q2FY22 | — | unread | -9.7% | -20.1% | -17.3% | +44% | no figures |
|
› |